Pancreatitis aguda recidivante con enteropatía por gluten asociada. Características clínico-analíticas y evolutivas en 34 pacientes / No disponible

Objetivos: describir la frecuencia y características clínico-analíticasde la pancreatitis aguda (PA) recidivante con enteropatíapor gluten (EG) asociada.Pacientes y métodos: estudiamos de forma prospectiva loscasos de pancreatitis agudas ingresados en nuestro Servicio duranteel año 2006. Registramos un total de 185 pacientes. A lasformas recurrentes que fueron 40 en total (22%), les aplicamos unprotocolo clínico-analítico consistente en la determinación demarcadores serológicos, genéticos y biopsias duodenales, paradescartar una EG asociada.Resultados: un total de 34 pacientes (18%) cumplían criteriosclínico-biológicos de EG asociada (grupo 1) y se compararon conel resto de las PA no-EG (n = 161) (grupo 2). La edad media en laEG fue de 54 ± 25 años, ligeramente inferior al grupo 2, (61 ±14) (NS). Existía un ligero predominio de mujeres (50%) en el grupo1, respecto al grupo 2 (38,5%) (NS). Siete pacientes del grupo1 (20%) presentaron una PA grave, frente a 27 (17%) en el grupo2 (NS). La presencia de colelitiasis en el grupo 1, fue de 6 casos(18%), significativamente inferior a la del grupo 2, de 72 casos(45%) (p < 0,05). Cuatro pacientes con EG desarrollaron seudoquistes(12%) frente a 13 (8%) en el grupo 2 (NS).La transglutaminasa tisular (TGt) estaba elevada únicamente en3 casos (9%). Nueve pacientes (34%) fueron DQ2 (+) y 4 (12%)DQ8 (+), siendo el resto (54%), negativos para ambos marcadores.Existía una duodenitis difusa desde el punto de vista endoscópicoen 32 pacientes (95%). Las biopsias duodenales, mostraronatrofia vellositaria (Marsh 3) en 2 casos (6%); infiltración inflamatoriade la submucosa (Marsh 2) en 10 casos (29,4%); aumento delos linfocitos intraepiteliales (Marsh 1) en 8 casos (23,5%) y mucosanormal (Marsh 0) en 14 casos (41,2%). La respuesta a la DSGal año, fue excelente en 30 pacientes (88%).Conclusiones: la PA recidivante con EG, constituye una asociaciónrelativamente frecuente, indistinguible desde el punto devista clínico y evolutivo del resto de PA, excepto por una menorpresencia de colelitiasis (p < 0,05)

Objectives: to describe the frequency and the clinical and laboratorycharacteristics of relapsing acute pancreatitis (AP) associatedwith gluten enteropathy (GE).Patients and methods: we prospectively examined all acutepancreatitis cases admitted to our Department in 2006. Werecorded a total of 185 patients. With recurring forms, 40 (22%)in all, we used a clinical-lab protocol including serologic and geneticmarkers, and duodenal biopsy to rule out GE.Results: a total of 34 patients (18%) met clinical-biological criteriafor GE (group 1), and were compared to the remaining non-GE AP cases (n = 161) (group 2). Mean age in the GE group was54 ± 25 years, slightly younger than group 2 (61 ± 14) (NS).There was a mild predominance of women (50%) in group 1 versusgroup 2 (38.5%) (NS). Seven patients in group 1 (20%) hadsevere AP, as compared to 27 (17%) in group 2 (NS). The presenceof cholelithiasis in group 1 involved 6 cases (18%), whichwas significantly lower than in group 2 – 72 cases (45%) (p <0.05). Four patients with GE developed pseudocysts (12%) versus13 (8%) in group 2 (NS).Tissue transglutaminase (tTG) was elevated only in 3 patients(9%). Nine patients (34%) were DQ2 (+) and 4 (12%) DQ8 (+); therest (54%) were all negative for both markers. From an endoscopicperspective there was diffuse duodenitis in 32 patients (95%).Duodenal biopsies revealed villous atrophy (Marsh 3) in 2 patients(6%); submucosal inflammatory infiltration (Marsh 2) in 10(29.4%); increased intraepithelial lymphocytes (Marsh 1) in 8 cases(23.5%), and normal mucosa (Marsh 0) in 14 patients (41.2%).Response to GFD after 1 year was excellent in 30 patients (88%).Conclusions: relapsing AP with GE represents a relativelycommon association that is indistinguishable from other APs froma clinical-evolutive stand point, except for a lower presence ofcholelithiasis (p < 0.05) (AU)

[Relapsing acute pancreatitis associated with gluten enteropathy. Clinical, laboratory, and evolutive characteristics in thirty-four patients]. / Pancreatitis aguda recidivante con enteropatía por gluten asociada, Características clínico-analíticas y evolutivas en 34 pacientes.

OBJECTIVES: To describe the frequency and the clinical and laboratory characteristics of relapsing acute pancreatitis (AP) associated with gluten enteropathy (GE). PATIENTS AND METHODS: We prospectively examined all acute pancreatitis cases admitted to our Department in 2006. We recorded a total of 185 patients. With recurring forms, 40 (22%) in all, we used a clinical-lab protocol including serologic and genetic markers, and duodenal biopsy to rule out GE. RESULTS: A total of 34 patients (18%) met clinical-biological criteria for GE (group1), and were compared to the remaining non-GE AP cases (n=161) (group2). Mean age in the GE group was 54 +/- 25 years, slightly younger than group 2 (61 +/- 14) (NS). There was a mild predominance of women (50%) in group 1 versus group 2 (38.5%) (NS). Seven patients in group 1 (20%) had severe AP, as compared to 27 (17%) in group 2 (NS). The presence of cholelithiasis in group 1 involved 6 cases (18%), which was significantly lower than in group 2--72 cases (45%) (p < 0.05). Four patients with GE developed pseudocysts (12%) versus 13 (8%) in group 2 (NS). Tissue transglutaminase (tTG) was elevated only in 3 patients (9%). Nine patients (34%) were DQ2 (+) and 4 (12%) DQ8 (+); the rest (54%) were all negative for both markers. From an endoscopic perspective there was diffuse duodenitis in 32 patients (95%). Duodenal biopsies revealed villous atrophy (Marsh 3) in 2 patients (6%); submucosal inflammatory infiltration (Marsh 2) in 10 (29.4%); increased intraepithelial lymphocytes (Marsh 1) in 8 cases (23.5%), and normal mucosa (Marsh 0) in 14 patients (41.2%). Response to GFD after 1 year was excellent in 30 patients (88%). CONCLUSIONS: Relapsing AP with GE represents a relatively common association that is indistinguishable from other APs from a clinical-evolutive standpoint, except for a lower presence of cholelithiasis (p < 0.05). A specific diagnostic protocol is much needed in the identification of these patients since GFD is the only effective therapy to prevent new AP events from developing.